文献速递肿瘤 PET/CT

68Ga-FAPI PET/CT对226例多种癌症患者分期与肿瘤学管理的影响

Impact of 68Ga-FAPI PET/CT on Staging and Oncologic Management in a Cohort of 226 Patients with Various Cancers.
PubMed 文献 · J Nucl Med · 2023-09-07

该回顾性分析纳入226例多种肿瘤患者,比较金标准影像与68Ga-FAPI PET/CT确定的TNM分期和肿瘤学管理。42%的患者TNM分期因68Ga-FAPI PET/CT而改变,多数为分期上调;117/226例临床管理发生改变,仅12%为重大改变,但计划放疗的准确性显著改善。

要点

  • 42%的患者TNM分期因68Ga-FAPI PET/CT改变,多数为分期上调。
  • 226例中117例临床管理发生改变,重大管理改变仅占12%。
  • 肺癌、胰腺癌和头颈肿瘤患者的临床影响最高。

核心结论

  • 68Ga-FAPI PET/CT是有前景的显像探针,对TNM分期和临床管理有显著影响。
  • 68Ga-FAPI PET/CT有望成为改善传统影像学方法(如增强CT和增强MRI)的关键新技术。

研究设计与样本

  • 回顾性分析纳入226例患者(137例男性、89例女性),胰腺癌和头颈癌是最常见肿瘤类型。
  • 先用金标准影像确定TNM分期和肿瘤学管理,再与68Ga-FAPI PET/CT结果比较,改变分为重大和次要。

主要发现

  • 42%的患者TNM分期因68Ga-FAPI PET/CT结果而改变,多数改变导致分期上调。
  • 226例中117例临床管理发生改变,仅12%的患者为重大管理改变。
  • 计划放疗的准确性显著改善。
  • 肺癌、胰腺癌和头颈肿瘤患者的临床影响最高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Since the development of fibroblast activation protein-targeted radiopharmaceuticals, 68Ga-fibroblast activation protein inhibitor (FAPI) PET/CT has been found to be suitable for detecting primary and metastatic lesions in many types of tumors. However, there is currently a lack of reliable data regarding the clinical impact of this family of probes. To address this gap, the present study aimed to analyze the clinical impact of 68Ga-FAPI PET/CT by examining a large cohort of patients with various tumors. Methods: In total, 226 patients (137 male and 89 female) were included in this retrospective analysis. Pancreatic cancer and head and neck cancers were the most common tumor types in this cohort. TNM stage and oncologic management were initially determined with gold standard imaging, and these results were compared with 68Ga-FAPI PET/CT. Changes were classified as major and minor. Results: For 42% of all patients, TNM stage was changed by 68Ga-FAPI PET/CT results. Most of these changes resulted in upstaging. A change in clinical management occurred in 117 of 226 patients. Although a major change in management occurred in only 12% of patients, there was a significant improvement in the ability to accurately plan radiation therapy. In general, the highest clinical impact of 68Ga-FAPI PET/CT imaging was found in patients with lung cancer, pancreatic cancer, and head and neck tumors. Conclusion: 68Ga-FAPI PET/CT is a promising imaging probe that has a significant impact on TNM stage and clinical management. 68Ga-FAPI PET/CT promises to be a crucial new technology that will improve on conventional radiologic imaging methods such as contrast-enhanced CT and contrast-enhanced MRI typically acquired for cancer staging.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Koerber SA, Röhrich M, Walkenbach L, et al. Impact of 68Ga-FAPI PET/CT on Staging and Oncologic Management in a Cohort of 226 Patients with Various Cancers. J Nucl Med. 2023. PMID: 37678928. doi:10.2967/jnumed.123.266046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。